Two thirds of COVID-19 patients improve after Gilead drug: NEJM

More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc. , according to new data based on patient observation.